Loading…
Loading…
Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Project BioShield related to Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens that prese.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have completed the transfer of all rights for RADICAVA (edaravone), including intellectual property rights and sales rights, in major countries and regions to our company from Tanabe Pharma Corporation. Transfer of rights in additional countries and regions is forthcoming. The acquisition and integration of RADICAVA team memb.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first patients were enrolled in Esprit, a global Phase 2 clinical trial evaluating S-606001, an investigational drug for the treatment of late-onset Pompe disease (LOPD). Esprit is a multicenter, randomized, placebo-controlled, double-blind study evaluating the safety, pharmacodynamics and preliminary efficacy of S-606001 as an o.
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2025 Earnings Conference Call July 28, 2025 3:30 AM ET Company Participants John A.
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Masako Kudou - VP, Finance & Accounting Department Kazuhiro Hatanaka - Senior Executive Officer, Corporate Supervisory Unit & Corporate Strategy Division Toshinobu Iwasaki - SVP, Healthcare Business Unit Takeki Uehara - SVP, Drug Development & Regulatory Science Division Conference Call Participants Hidemaru Yamaguchi - Citi Eiji Ueda - Goldman Sachs Fumiyoshi Sakai - UBS Kazuaki Hashiguchi - Daiwa Securities Shinya Tsuzuki - Mizuho Securities Shinichiro Muraoka - Morgan Stanley Seiji Wakao - JPMorgan Yoshimasa Kyokawa This is Kyokawa of the Corporate Communication Department of Shionogi.
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Isao Teshirogi - Chairman, President, and CEO John Keller - Senior Vice President, R&D, Supervisory Unit Takeki Uehara - Senior Vice President, Drug Development and Regulatory Science Division Toshinobu Iwasaki - Senior Vice President, Healthcare Business Unit Koji Hanasaki - Senior Vice President, Supply Supervisory Unit, Global Business Division Masako Kudou - Vice President, Finance and Accounting Department Conference Call Participants Hidemaru Yamaguchi - Citi Eiji Ueda - Goldman Sachs Kasumi Haruta - UBS Kazuaki Hashiguchi - Daiwa Securities Seiji Wakao - JPMorgan Shinya Tsuzuki - Mizuho Securities Miki Sogi - Bernstein Hiroyuki Matsubara - Nomura Securities Yoshimasa Kyokawa Ladies and gentlemen, time to start today's meeting.
No recent filings indexed.